枸橼酸托瑞米芬治疗管腔上皮型乳腺癌年轻患者的疗效与安全性研究  

Study on the effect and safety of toremifene citrate in treatment of type Luminal breast cancer in young patients

作　　者：李莉[1] 王建军[1] 

机构地区：[1]云南省第一人民医院乳腺甲状腺肿瘤外科,昆明650000

出　　处：《检验医学与临床》2014年第18期2521-2522,2531,共3页Laboratory Medicine and Clinic

基　　金：云南省科技厅支助基金项目(CF-2010LN)

摘　　要：目的探讨枸橼酸托瑞米芬治疗管腔上皮(Luminal)型乳腺癌年轻患者的效果与安全性。方法将2008年1月至2011年12月云南省第一人民医院确诊的160例Luminal型乳腺癌年轻患者随机分为研究组与对照组,每组各80例。根据患者病情给予局部手术+放射治疗+局部化学治疗+内分泌治疗。研究组内分泌治疗给予枸橼酸托瑞米芬,对照组给予枸橼酸他莫昔芬,比较两组复发、转移、生存情况及不良反应发生率。结果研究组无复发/转移生存率明显高于对照组(P<0.05),两组间复发/转移生存率和病死率比较差异无统计学意义(P>0.05)。研究组远端复发率明显高于对照组,转移率明显低于对照组(P<0.05);两组间局部复发率比较差异无统计学差异(P>0.05)。研究组患者不良反应率为32.5%(26/80),与对照组的33.8%(27/80)对比,比较差异无统计学意义(P>0.05)。结论应用枸橼酸托瑞米芬治疗Luninal型乳腺癌年轻患者疗效明显,且安全可靠,可作为枸橼酸他莫昔芬的替代性用药。Objective To investigate the effect and safety of toremifene citrate in the treatment of type Luminal breast cancer in young patients.Methods One hundred and sixty young patients with type Luminal breast cancer from 2008 January to 2011 December were randomly divided into study group and control group,80 patients in each group.Patients were treated with local surgery,radiotherapy,chemotherapy and endocrine therapy according to the condition of patients.The patients in the study group were treated with toremifene citrate for endocrine therapy,the patients in the control group were given tamoxifen citrate,then compared the recurrence,metastasis,survival situation and the incidence of adverse reactions of the two groups.Results The rate of no recurrence/metastasis survival in the study group was significant higher than that in the control group（P〈0.05）.There was no significant difference on the rate of recurrence/metastasis survival and mortality between the two groups（P〈0.05）.The rate of distant recurrence in the study group was significant higher than that in the control group（P〉0.05）,the rate of transfer was significant lower than that in the control group（P〈0.05）,no significant difference found on local recurrence rate between the two groups（P〉0.05）.The incidences of adverse reaction in the study group and the control group were32.5%（26/80）and 33.8%（27/80）respectively,there was no significant difference between the two groups（P〉0.05）.Conclusion Toremifene citrate could be used as alternative drug of tamoxifen for type Luninal breast cancer in young patients because of its effect and safety.

关 键 词：年轻患者 乳腺癌 Luminal型 枸橼酸托瑞米芬 疗效 安全性 

分 类 号：R979.1[医药卫生—药品]